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Introduction: Antibodies against mimivirus, a recently discovered giant virus, have been found in
patients presentingwith pneumonia suggesting a potential role for this virus as a respiratory path-
ogen. Several bacterial and viral pathogens have been associated with the occurrence of acute
exacerbations in COPD. However, a large part of these exacerbations have an unknown cause.
In the present studywe evaluated the presence ofmimivirus in sputum samples of COPD patients.
Methods: From March 2009 until January 2010 all sputum samples collected during stable condi-
tions and during exacerbations of COPD patients, referred for pulmonary rehabilitation, were
included. All sputum samples were analysed by real-time PCR targeting mimivirus. Furthermore,
serum samples were analysed for the presence of antibodies against mimivirus.
Results: A total of 220 sputum samples from 109 patients were eligible for inclusion. None of the
sputum samples showed the presence of mimivirus DNA. Antibodies against mimivirus were de-
tected in 3 serum samples from 3 patients, of which one showed an increase in antibody-titre.
Conclusions: Although mimivirus was suggested as a potential respiratory pathogen, its presence
could not be confirmed in the present study-population of patients with COPD.
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Mimivirus in COPD patients 1691Introduction filters were placed in 5 ml sterile water and sonicated forChronic obstructive pulmonary disease (COPD) is an
inflammatory lung disease, which is characterized by the
presence of acute exacerbations (AE).1 These exacerba-
tions form a large social burden and have a significant
effect on the quality of life of the COPD patient. Exacer-
bations can be caused by a complex interaction between
different factors: the host, bacteria, viruses and the envi-
ronment.2 Microorganisms are thought to play a major role
in the occurrence of AE.3e7 Many bacteria, such as Hae-
mophilus influenza and Pseudomonas aeruginosa, and
viruses, such as rhinovirus and human metapneumovirus
(hMPV), are already associated with the occurrence of
AE.3,6 However, in a significant part of the AE, no micro-
organism is found.
Acanthamoeba polyphaga mimivirus (mimivirus) is
a recently discovered giant DNA virus, which belongs to the
amoeba-associated microorganisms.8 Other amoeba-
associated microorganisms, like Legionella pneumophila,
are known to cause pneumonia in different patient pop-
ulations. Previous studies suggest a potential role for
mimivirus in respiratory pathology. Seroconversion to
mimivirus was shown in patients with community-acquired
pneumonia9 and in patients with nosocomial pneumonia.10
In addition, positive serology for mimivirus was associated
with an increased duration of mechanical ventilation and
intensive care unit (ICU) stay in patients with ventilator-
associated pneumonia (VAP).11 Because of the potential
role of mimivirus as a respiratory pathogen, we evaluated
the presence of mimivirus DNA in sputum and the presence
of antibodies against mimivirus in serum samples of COPD
patients, referred for pulmonary rehabilitation.
Methods
Sampling technique
The study was performed at Ciro, a centre of expertise for
chronic organ failure in Horn, The Netherlands. During a 10
month period (March 2009 until January 2010) sputum and
serum samples from COPD patients participating in
a pulmonary rehabilitation program, were collected.
Patients stay at the centre for 8 consecutive weeks. During
the stay in the centre, sputum and serum samples are
collected at different time points: at the beginning and end
of the rehabilitation program, when they are stable, and
when an acute exacerbation occurs (Fig. 1).
Sputum samples were excluded for the detection of
mimivirus DNA when no sufficient amount of sputum sample
was present for isolation of the DNA.
Additional samples
To identify possible infectious sources of mimivirus in and
near Ciro, water samples were collected. These samples
included water samples obtained from taps located at Ciro
and samples obtained in the vicinity of Ciro. Samples were
filtered through 0.2 mm polycarbonate filters (Sartorius
Stedim biotech, Goettingen, Germany). Afterwards the5 min in a sonication bath (Bandelin electronic GmbH & Co.
KG, Berlin, Germany) at 40 kHz.
Laboratory processing
The collected sputum samples were used for bacterial
culture and for the detection of respiratory viruses. The
remaining sputum was divided into different fractions of
which one was used retrospectively for the detection of
mimivirus DNA. Serum was divided into 5 fractions and
stored at 80 C until analysis could be performed.
Mimivirus real-time PCR (RT-PCR)
A total of 100 ml of the stored fraction of sputum and of the
filtered water samples was used for DNA isolation using the
4 M GuanidineeIsothiocyanate (GTC)/Phenol/Chloroform
(CHCL3) extraction technique. In short GTC, phenol and
CHCL3 were added to the sputum and centrifuged. The
water phase was extracted with phenol/CHCL3 and after
another centrifugation step, 0.7 volumes iso-propanol, 0.1
volume 3 M Sodium acetate and 1 ml glycogen were added.
The pellet was incubated for 10 min, centrifuged, washed
with 70% ethanol and dried. The isolated DNA was resus-
pended in 100 ml nuclease free water. Each sample was
spiked before DNA isolation with a control plasmid con-
taining 106 part of the murine cytomegalovirus gene
encoding the glycoprotein B (mCMV-gb). This served as an
isolation and amplification control. The above mentioned
protocol was also used for the isolation of DNA out of the
collected water samples.
An in-house PCR was performed using primers and
probes, designed with the Primer3 software, which target
the Mimi L396 VV A18 helicase gene (Table 1). Assays were
performed in a 96-well Optical Reaction plate (Applied
Biosystems, Foster City, California) in a total volume of
25 ml which contained 0.3 mM forward primer, 0.3 mM
reverse primer, 0.1 mM probe, 12.5 ml ABsolute QPCR Mas-
termix (ABgene, Epsom, UK) and 5 ml DNA. A positive
control for mimivirus was kindly provided by Prof. Raoult.
This control was used for the detection of mimvirus in
patient samples and in water samples. Gel-electrophoresis
was used to test positive PCR results.
The PCR reactions for the isolation and amplification
control (mCMV-gb) were carried out using primers and
a probe described previously.12 The PCR thermal profile for
both mimivirus and mCMV-gb consisted of an initial incu-
bation of 15 min at 95 C followed by a total of 43 cycles of
amplification (15 s at 95 C and 1 min at 60 C). Amplifi-
cation was performed using the ABI Prism 7000 Sequence
Detection System (ABI) and data were interpreted using the
ABI Prism SDS software 2.2.
Mimivirus serology
Stored serum samples were analysed for the presence of
antibodies against mimivirus by using immunofluorescence
as described previously.9 The serology was performed in the
lab of Prof. Raoult. Evidence of a serologic reaction to
Figure 1 Schematic reproduction of the different sampling moments.
Table 2 Patient characteristics from all included
patients.
Number of patients (n Z 109)
Male/female ratio 1:0.9
Mean age (years) 66
GOLD stagea
Stage I 20
Stage II 39
Stage III 27
1692 M.J. Vanspauwen et al.mimivirus was defined as 1) an increase in antibody titre
from <1:50 to  1:100, 2) a four-fold rise in antibody titre
or 3) single or stable titre of 1:400 (Table 1).
Results
Patients included
From March 2009 until January 2010, a total of 220 sputum
samples were collected from 109 patients. Patients had
a mean age of 66 years (range 42e85), and the male-to-
female ratio was 1:0.9. Patient characteristics for all
included patients are shown in Table 2.
Sample information
A total of 115 out of 220 sputum samples (52%) were
collected during the stable phase of the rehabilitation
program, of which 72 were collected at inclusion and 43 at
the end of the revalidation program. A total of 11 patients
only had an inclusion and end sample. During an acute
exacerbation, 105 samples were collected of 74 patients.
Stable samples were not obtained in 25 of 74 patients with
an exacerbation. Of 17 patients sputum samples were
present at inclusion, acute exacerbation and at the end of
the revalidation program (Fig. 2). A total of 118 serum
samples were tested for the presence of mimivirus serology
of which 30 were collected during an exacerbation and 88
during the stable phase.
Mimivirus PCR
Out of the 220 sputum samples included, two samples
showed a weak positive RT-PCR result with a high Ct-value
(both Ct 35). Repetition of the RT-PCR on the two samples
showed a negative result for both. Additionally, the RT-PCRTable 1 Primers and probe targeting the Mimi L396 VV
A18 helicase gene, designed with the Primer3 software.
Forward primer TTCTAGCACCCATGTGATGA
Reverse primer TCCTTTTGTAGTTTCAATGGTTCA
Probe ATCTCGTCGTTG TAATTTATCTTTGCTresults were tested by means of gel-electrophoresis.
However, no positive band could be detected in either
sample. Therefore these samples were classified as nega-
tive. Moreover, mimivirus DNA was also not detected in
water samples collected in the vicinity of Ciro in the
southern part of the Netherlands (data not shown).
Mimivirus serology
Three serum samples of 3 different patients (2.5%) showed
antibodies against mimivirus (Fig. 3). Two of the samples
were collected during an exacerbation and one during the
stable phase. Only in one patient (patient 110) an increase
in antibody titre could be observed. Patient characteristics
of sero-positive patients are shown in Table 3.
Discussion
Since its discovery, mimivirus has been linked to respiratory
pathology. Different studies have shown a potential role for
the virus in patients with community acquired pneumonia,9
nosocomial pneumonia10 and VAP.11 All these results were
based on serology and PCR.
In the present study no mimivirus DNA was detected in
sputum samples of COPD patients by means of RT-PCR. The
results of the present study were in line with two otherStage IV 21
Mean AE previous year 2
Smoking state
Smoker 31
Quit smoking 78
a Of 2 patients no lung function tests could be performed.
Figure 2 Number of patients with a sputum sample at every
sampling moment AE Z acute exacerbation.
Mimivirus in COPD patients 1693recent studies. Dare et al.13 screened 496 pneumonia cases
in different patient populations for the presence of mim-
ivirus by means of an RT-PCR. Although they (mainly) tested
nasal and nasopharyngeal aspirates, they could not detect
mimivirus DNA with their RT-PCR. Larcher et al.14 tested
214 nasopharyngeal aspirate samples from children, hospi-
talized for respiratory tract infections, for the presence of
different respiratory viruses, including mimivirus. Mimivirus
could not be detected in any of the respiratory samples
tested by mimivirus-specific PCR. In contrast to these
results, La Scola et al.,9 detected mimivirus DNA in a bron-
choalveolar lavage (BAL) specimen from a comatose patient
with two episodes of hospital-acquired pneumonia (HAP)
while staying at ICU. Mimivirus DNA was only detected in
a BAL fluid sample obtained during the second episode ofFigure 3 Mimivirus serolgy results from positive patients. Time bsuspected HAP, suggesting that it was acquired during
hospitalization. Acquisition of the virus could have occurred
by the use of contaminated water.
In the present study, three patients had antibodies
against the mimivirus. In patient C a seroconversion was
seen between day 0 (admission) and day 13 (exacerbation).
Since it takes approximately four weeks to produce anti-
bodies, the viral infection may have occurred before the
patient was admitted to the rehabilitation centre. There-
fore the virus may have been no longer present at admission
when the first sputum sample was taken, making it an
unlikely cause of the exacerbation, but explaining the
positive serology. Patient B was already seropositive at
admission, indicating that the contact with mimivirus had
already occurred. Unfortunately, interpreting the serology
of the remaining seropositive patient was challenging, since
only one serum sample was available for patient A, taken at
exacerbation. Therefore it is impossible to say when the
contact with the viral agent occurred. Several studies
showed the presence of antibodies against mimivirus in
different patient populations. A study performed in
a Canadian population, showed the presence of antibodies
to mimivirus in 9.7% of patients with community-acquired
pneumonia9 and in 2.3% in the healthy population. Berger
et al.10 sampled all patients admitted to the ICU, clinically
suspected of pneumonia. Antibodies against mimivirus were
detected in 7.1% of patients diagnosed with pneumonia
included in that study. A case-control study performed on
an ICU11 determined the mimivirus sero-status of the
admitted patients. All mechanically ventilated patients
with a suspicion of VAP were sampled. Acute and
convalescent-phase serum samples were tested for the
presence of antibodies against mimivirus by an immuno-
fluorescence assay. A total of 19.7% of the ICU patients with
a suspicion of VAP were sero-positive for mimivirus.
Furthermore, sero-positivity for mimivirus was associated
with an increased duration of both mechanical ventilation
and ICU stay. In our study, in only 2.5% of the patients,
mimivirus antibodies were found. These results are lower
than found in the previously mentioned studies,9e11 butetween samples (t) Shown in days. AE Z acute exacerbation.
Table 3 Patient characteristics of sero-positive patients.
Patient A Patient B Patient C
Sex Male Male Female
Age 80 58 73
GOLD stage I II I
Timepoint
sero-positivity
Acute
exacerbation
Inclusion Acute
exacerbation
AE previous year 6 5 3
Smoking state Quit smoking Quit smoking Quit smoking
1694 M.J. Vanspauwen et al.comparable to the results found in a control population by
La Scola et al.9 The low sero-positivity might be explained
by a low abundance of the virus or the presence of the virus
might be subject to regional variation. This idaea is sup-
ported by the fact that different water supplies in different
locations also tested negative for the presence of mimivirus
DNA. Furthermore, the incidence of Legionella infections is
also prone to regional variation. For example, the incidence
of infections has decreased in the Netherlands from 1999 to
2004, while in France, the incidence has increased in the
same time period and is higher than in the Netherlands.15,16
Since mimivirus is a Legionella-like microorganism, this
might explain the low sero-positivity seen in the present
study. This is supported by the findings of Berger et al.,10
who found a high percentage of Legionella infections
(4.8%) and also a high percentage of mimivirus (7.1%) in
a study population in Marseille.
A number of possible explanations should be considered
in interpreting the negative PCR results. First, the viral load
of the samples may have been below the detection limit of
the PCR (12 copies/reaction). Another explanation could be
that a polymorphism in the area of amplification occurred,
which would lead to negative PCR results. This hypothesis
can be supported by the recent discovery of more
mimivirus-related viruses. Due to the wide genomic diver-
sity of these different mimivirus-related viruses it is
possible that PCR could not detect them.17,18 The third
explanation could be that the virus resides in the lower
respiratory tract and sputum might not be the material of
choice for the detection of mimivirus. The latter may be
supported by the finding that the only PCR positive sample
for mimivirus was a BAL fluid sample.9 Furthermore, the
discrepant results between serology and PCR may be
a result of the timing in which the samples were taken.
To our knowledge, this is the first study dealing with
COPD patients, whilst most of the previously described
studies were conducted with seriously ill patients, mostly
ventilated. Since the aim of the present study was to
investigate the role of mimivirus in AE COPD, the focus was
towards detecting the virus in respiratory samples obtained
from COPD patients. Until now, a clear role of the mimivirus
in AE COPD could not be determined.
Conclusion
At present, mimivirus DNA could not be detected in sputum
samples from COPD patients during their stable phase or
during acute exacerbations.Ethical approval
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